Paradoxical stimulation of prolactin secretion by L-Dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia

Paolo Lissoni, Mario Mandalà, Franco Rovelli, Marina Casu, Francesco Rocco, Gabriele Tancini, Epifanio Scardino

Research output: Contribution to journalArticle

Abstract

Objective: In addition to sex steroids, prolactin (PRL) may also stimulate prostate cancer growth. Abnormally high blood levels of PRL have been noted in metastatic prostate cancer patients. However, most studies have been limited to the evaluation of basal levels of PRL rather than to investigate its secretion in response to classical endocrine dynamic tests. This study was carried out to analyze PRL secretion in metastatic prostate cancer patients both at basal conditions and in response to L-Dopa and metoclopramide, which represents the most classical inhibitory and stimulatory tests for PRL secretion, respectively. Methods: The study included 12 patients with metastatic prostate cancer. On separate occasions, PRL secretion was evaluated in response to L-Dopa (500 mg orally) and to metoclopramide (10 mg i.v. as a bolus). Serum levels of PRL were measured by RIA. Results: Mean PRL concentrations significantly increased after metoclopramide administration, even though no PRL response occurred in 6 of 12 patients. L-Dopa was unable to reduce PRL levels, which, in contrast, paradoxically significantly increased in response to L-Dopa, with mean values comparable to those achieved after metoclopramide injection. Conclusion: By showing a paradoxical stimulatory effect of L-Dopa on PRL secretion and a lack of response to metoclopramide in some patients, this study would suggest the existence of evident alterations in the neuroendocrine regulation of PRL release in advanced prostate cancer. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)569-572
Number of pages4
JournalEuropean Urology
Volume37
Issue number5
Publication statusPublished - 2000

Fingerprint

Hyperprolactinemia
Levodopa
Prolactin
Prostatic Neoplasms
Metoclopramide
Steroids

Keywords

  • L-Dopa
  • Prolactin
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Lissoni, P., Mandalà, M., Rovelli, F., Casu, M., Rocco, F., Tancini, G., & Scardino, E. (2000). Paradoxical stimulation of prolactin secretion by L-Dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia. European Urology, 37(5), 569-572.

Paradoxical stimulation of prolactin secretion by L-Dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia. / Lissoni, Paolo; Mandalà, Mario; Rovelli, Franco; Casu, Marina; Rocco, Francesco; Tancini, Gabriele; Scardino, Epifanio.

In: European Urology, Vol. 37, No. 5, 2000, p. 569-572.

Research output: Contribution to journalArticle

Lissoni, P, Mandalà, M, Rovelli, F, Casu, M, Rocco, F, Tancini, G & Scardino, E 2000, 'Paradoxical stimulation of prolactin secretion by L-Dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia', European Urology, vol. 37, no. 5, pp. 569-572.
Lissoni, Paolo ; Mandalà, Mario ; Rovelli, Franco ; Casu, Marina ; Rocco, Francesco ; Tancini, Gabriele ; Scardino, Epifanio. / Paradoxical stimulation of prolactin secretion by L-Dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia. In: European Urology. 2000 ; Vol. 37, No. 5. pp. 569-572.
@article{07403ae681264876ab65f51037d75521,
title = "Paradoxical stimulation of prolactin secretion by L-Dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia",
abstract = "Objective: In addition to sex steroids, prolactin (PRL) may also stimulate prostate cancer growth. Abnormally high blood levels of PRL have been noted in metastatic prostate cancer patients. However, most studies have been limited to the evaluation of basal levels of PRL rather than to investigate its secretion in response to classical endocrine dynamic tests. This study was carried out to analyze PRL secretion in metastatic prostate cancer patients both at basal conditions and in response to L-Dopa and metoclopramide, which represents the most classical inhibitory and stimulatory tests for PRL secretion, respectively. Methods: The study included 12 patients with metastatic prostate cancer. On separate occasions, PRL secretion was evaluated in response to L-Dopa (500 mg orally) and to metoclopramide (10 mg i.v. as a bolus). Serum levels of PRL were measured by RIA. Results: Mean PRL concentrations significantly increased after metoclopramide administration, even though no PRL response occurred in 6 of 12 patients. L-Dopa was unable to reduce PRL levels, which, in contrast, paradoxically significantly increased in response to L-Dopa, with mean values comparable to those achieved after metoclopramide injection. Conclusion: By showing a paradoxical stimulatory effect of L-Dopa on PRL secretion and a lack of response to metoclopramide in some patients, this study would suggest the existence of evident alterations in the neuroendocrine regulation of PRL release in advanced prostate cancer. Copyright (C) 2000 S. Karger AG, Basel.",
keywords = "L-Dopa, Prolactin, Prostate cancer",
author = "Paolo Lissoni and Mario Mandal{\`a} and Franco Rovelli and Marina Casu and Francesco Rocco and Gabriele Tancini and Epifanio Scardino",
year = "2000",
language = "English",
volume = "37",
pages = "569--572",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Paradoxical stimulation of prolactin secretion by L-Dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia

AU - Lissoni, Paolo

AU - Mandalà, Mario

AU - Rovelli, Franco

AU - Casu, Marina

AU - Rocco, Francesco

AU - Tancini, Gabriele

AU - Scardino, Epifanio

PY - 2000

Y1 - 2000

N2 - Objective: In addition to sex steroids, prolactin (PRL) may also stimulate prostate cancer growth. Abnormally high blood levels of PRL have been noted in metastatic prostate cancer patients. However, most studies have been limited to the evaluation of basal levels of PRL rather than to investigate its secretion in response to classical endocrine dynamic tests. This study was carried out to analyze PRL secretion in metastatic prostate cancer patients both at basal conditions and in response to L-Dopa and metoclopramide, which represents the most classical inhibitory and stimulatory tests for PRL secretion, respectively. Methods: The study included 12 patients with metastatic prostate cancer. On separate occasions, PRL secretion was evaluated in response to L-Dopa (500 mg orally) and to metoclopramide (10 mg i.v. as a bolus). Serum levels of PRL were measured by RIA. Results: Mean PRL concentrations significantly increased after metoclopramide administration, even though no PRL response occurred in 6 of 12 patients. L-Dopa was unable to reduce PRL levels, which, in contrast, paradoxically significantly increased in response to L-Dopa, with mean values comparable to those achieved after metoclopramide injection. Conclusion: By showing a paradoxical stimulatory effect of L-Dopa on PRL secretion and a lack of response to metoclopramide in some patients, this study would suggest the existence of evident alterations in the neuroendocrine regulation of PRL release in advanced prostate cancer. Copyright (C) 2000 S. Karger AG, Basel.

AB - Objective: In addition to sex steroids, prolactin (PRL) may also stimulate prostate cancer growth. Abnormally high blood levels of PRL have been noted in metastatic prostate cancer patients. However, most studies have been limited to the evaluation of basal levels of PRL rather than to investigate its secretion in response to classical endocrine dynamic tests. This study was carried out to analyze PRL secretion in metastatic prostate cancer patients both at basal conditions and in response to L-Dopa and metoclopramide, which represents the most classical inhibitory and stimulatory tests for PRL secretion, respectively. Methods: The study included 12 patients with metastatic prostate cancer. On separate occasions, PRL secretion was evaluated in response to L-Dopa (500 mg orally) and to metoclopramide (10 mg i.v. as a bolus). Serum levels of PRL were measured by RIA. Results: Mean PRL concentrations significantly increased after metoclopramide administration, even though no PRL response occurred in 6 of 12 patients. L-Dopa was unable to reduce PRL levels, which, in contrast, paradoxically significantly increased in response to L-Dopa, with mean values comparable to those achieved after metoclopramide injection. Conclusion: By showing a paradoxical stimulatory effect of L-Dopa on PRL secretion and a lack of response to metoclopramide in some patients, this study would suggest the existence of evident alterations in the neuroendocrine regulation of PRL release in advanced prostate cancer. Copyright (C) 2000 S. Karger AG, Basel.

KW - L-Dopa

KW - Prolactin

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0034072656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034072656&partnerID=8YFLogxK

M3 - Article

C2 - 10765095

AN - SCOPUS:0034072656

VL - 37

SP - 569

EP - 572

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -